Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$17,058 | -$30,733 | -$31,918 | -$32,940 |
| Dep. & Amort. | $198 | $197 | $201 | $203 |
| Deferred Tax | -$8,028 | $3,942 | $3,743 | $0 |
| Stock-Based Comp. | $3,830 | $5,281 | $5,403 | $5,404 |
| Change in WC | -$3,150 | $1,059 | -$1,970 | $357 |
| Other Non-Cash | $6,843 | -$5,281 | -$4,882 | -$744 |
| Operating Cash Flow | -$17,365 | -$25,535 | -$29,423 | -$27,720 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | $0 | $9 | -$9 |
| Net Acquisitions | -$9,133 | $0 | $11 | -$55 |
| Inv. Purchases | -$19,154 | -$29,319 | -$73,149 | -$33,097 |
| Inv. Sales/Matur. | $41,854 | $71,952 | $62,256 | $88,526 |
| Other Inv. Act. | $0 | $0 | -$11 | $55 |
| Investing Cash Flow | $13,567 | $42,633 | -$10,884 | $55,420 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $0 | $57 | $1,251 | $17 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $9,133 | $57 | $1,251 | -$9,116 |
| Financing Cash Flow | $9,133 | $57 | $1,251 | -$9,116 |
| Forex Effect | $1 | -$11,874 | $43,938 | $0 |
| Net Chg. in Cash | $5,336 | $17,155 | -$39,063 | $18,584 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $51,662 | $34,878 | $73,941 | $55,357 |
| End Cash | $56,998 | $52,033 | $34,878 | $73,941 |
| Free Cash Flow | -$17,365 | -$25,535 | -$29,414 | -$27,729 |